Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Shooter 

Biogen Inc. diskutieren

Biogen Inc.

WKN: 789617 / Symbol: BIIB / Name: Biogen / Aktie / Pharmazeutika / Large Cap /

195,30 €
3,26 %

Einschätzung Buy
Rendite (%) -4,82 %
Kursziel 256,09
Veränderung
Endet am 22.02.25

Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $355.00 to $277.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,13 %
Kursziel 334,73
Veränderung
Endet am 05.03.25

Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $364.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat

Einschätzung Buy
Rendite (%) -2,11 %
Kursziel 313,72
Veränderung
Endet am 25.03.25

Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $340.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat

Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for BIIB provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,27 %
Kursziel 275,07
Veränderung
Endet am 24.04.25

Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $294.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat

Einschätzung Buy
Rendite (%) 2,90 %
Kursziel 280,50
Veränderung
Endet am 25.04.25

Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at HC Wainwright from $325.00 to $300.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat